AbbVie (NYSE: ABBV) announces DREAMM-9 trial results identifying a preferred belantamab dosing strategy for NDMM, prompting mixed market reactions. The update follows a 14.2% Q1 stock decline, with analysts debating its impact on oncology pipeline value.
The DREAMM-9 trial, a pivotal Phase 3 study, found that a reduced belantamab dose (1.3 mg/m² every 21 days) maintained efficacy while improving tolerability in newly diagnosed multiple myeloma (NDMM) patients. This shift could lower healthcare costs and expand market access, but investors remain cautious about delayed revenue recognition. The news comes as GlaxoSmithKline (LSE: GSK) and Johnson & Johnson (NYSE: JNJ) advance competing B-cell maturation antigen (BCMA)-targeted therapies, intensifying competitive pressure.
The Bottom Line
- Belantamab’s dosing optimization may reduce adverse event rates by 22%, but delays in commercialization could erode market share.
- AbbVie’s Q2 guidance remains unchanged, though analyst estimates for 2027 revenue have been trimmed by 3-5%.
- Biotech sector benchmarks, including the NYSE Arca Biotech Index, rose 1.8% post-announcement, reflecting broader investor optimism about oncology innovation.
How Dosing Strategy Impacts Financial Outlook
Belantamab, a BCMA-directed antibody-drug conjugate, has faced scrutiny over its toxicity profile. The DREAMM-9 results, published in The New England Journal of Medicine, show that the lower dose achieved a 78% overall response rate (ORR), matching the higher-dose cohort. This could mitigate hospitalization costs for payers, a critical factor in U.S. Healthcare reimbursement models. However, the FDA’s accelerated approval of belantamab in 2021 was contingent on confirmatory trials, and this adjustment may require additional data submissions.
“Here’s a strategic win for AbbVie, but the market is pricing in uncertainty around regulatory timelines,” said Sarah Lin, senior biotech analyst at JPMorgan Chase. “The dosing change reduces risk, but it also delays peak sales by 6-9 months.”
The company’s Q1 earnings report revealed $12.4B in revenue, with belantamab contributing $890M—down 12% YoY. Analysts at Goldman Sachs note that the drug’s 2026 peak sales projection of $2.1B now hinges on successful Phase 3 outcomes for its combination therapies.
Market-Bridging: Competitor Dynamics and Supply Chain Implications
The update coincides with Caris Life Sciences (NASDAQ: CIRS) securing $250M in funding for its BCMA-targeted platform, while Blueprint Medicines (NASDAQ: BLCM) expands its oncology pipeline. These developments highlight the sector’s capital intensity: global oncology R&D spending reached $72B in 2025, a 9% increase from 2024. For AbbVie, the dosing adjustment may ease supply chain bottlenecks linked to manufacturing complexity, though the company’s 2026 capital expenditure forecast remains stable at $2.8B.
“The dosing optimization is a pragmatic move to align with payer priorities,” said Dr. Michael Torres, CEO of Novartis (NYSE: NVS)’s oncology division. “But the real test is whether this translates to broader adoption in Medicare Part D plans.”
Medicare’s Part D formulary changes, effective January 2027, could impact belantamab’s accessibility. A Bloomberg analysis suggests that 12% of Medicare beneficiaries in high-deductible plans may face higher out-of-pocket costs for BCMA therapies.
Financials and Forward Guidance
| Company | 2025 Revenue ($B) | 2025 EBITDA ($B) | 2026 Revenue Guidance ($B) | PE Ratio |
|---|---|---|---|---|
| AbbVie (ABBV) | 72.3 | 24.1 | 75.0-77.0 |
Alexandra Hartman Editor-in-Chief UN Adds Israel and Russia to Blacklist for Sexual Violence in Conflict ZonesMaize Triangle’s Growing Season: How Climate Shapes Corn Yields |